Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
75 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Hypoglycemia - Pipeline Review, H1 2016 Summary
Global Markets Direct's, 'Hypoglycemia - Pipeline Review, H1 2016', provides an overview of the Hypoglycemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hypoglycemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypoglycemia and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Hypoglycemia - The report reviews pipeline therapeutics for Hypoglycemia by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Hypoglycemia therapeutics and enlists all their major and minor projects - The report assesses Hypoglycemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Hypoglycemia Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Hypoglycemia - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Hypoglycemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Hypoglycemia Overview 7 Therapeutics Development 8 Pipeline Products for Hypoglycemia - Overview 8 Hypoglycemia - Therapeutics under Development by Companies 9 Hypoglycemia - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Unknown Stage Products 13 Hypoglycemia - Products under Development by Companies 14 Hypoglycemia - Companies Involved in Therapeutics Development 15 Biodel Inc. 15 Eiger BioPharmaceuticals, Inc. 16 Eli Lilly and Company 17 Heptares Therapeutics Limited 18 Novartis AG 19 Sanofi 20 SkyePharma Plc 21 Therakind Limited 22 USV Limited 23 XERIS Pharmaceuticals, Inc. 24 XOMA Corporation 25 Zealand Pharma A/S 26 Hypoglycemia - Therapeutics Assessment 27 Assessment by Monotherapy Products 27 Assessment by Target 28 Assessment by Mechanism of Action 30 Assessment by Route of Administration 32 Assessment by Molecule Type 34 Drug Profiles 36 AMG-5041 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Biologic for Hypoglycemia - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Drug for Hypoglycemia - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 exendin-(9-39) - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 glucagon - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 glucagon - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 glucagon - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 glucagon - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 LY-3143753 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 LY-3185643 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 pasireotide - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 SAR-438544 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Small Molecule to Antagonize GLP-1 Receptor Hypoglycemia - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 terbutaline sulphate MR - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 XOMA-129 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 XOMA-358 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 ZP-4207 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Hypoglycemia - Recent Pipeline Updates 56 Hypoglycemia - Dormant Projects 64 Hypoglycemia - Discontinued Products 65 Hypoglycemia - Product Development Milestones 66 Featured News & Press Releases 66 Feb 04, 2016: Zealand initiates dosing of patients in Phase 2 with its stable glucagon analogue, ZP4207, for hypoglycemia in diabetes 66 Oct 26, 2015: XOMA Initiates Proof-of-Concept Study for XOMA 358 in Patients with Congenital Hyperinsulinism 66 Oct 13, 2015: Zosano Pharma Announces Positive Phase 2 Results for Its ZP-Glucagon Patch Program for Treatment of Severe Hypoglycemia 67 Sep 09, 2015: Results from a multiple-dose Phase Ib trial support the potential of Zealand's stable glucagon analogue, ZP4207, for the correction of mild to moderate hypoglycemia 67 Jun 26, 2015: Phase I trial results for Zealand's glucagon analogue, ZP4207 support its further development as a ready-to-use rescue treatment for severe hypoglycemia in diabetes patients on insulin therapy 68 Jun 23, 2015: Zosano Pharma Completes Enrollment in Phase 2 Trial for ZP-Glucagon, Its Microneedle Patch for Treatment of Severe Hypoglycemia 69 May 20, 2015: Zealand starts clinical development of a multiple-dose version of its stable glucagon analogue, ZP4207 69 Mar 16, 2015: Biodel's Glucagon Formulation for Use in a Proprietary Auto-Reconstitution Device for the Treatment of Severe Hypoglycemia Meets Primary Efficacy Endpoint in Phase 1 Clinical Trial 70 Mar 07, 2015: XOMA Presents Positive Phase 1 XOMA 358 Data at the ENDO Meeting 72 Mar 05, 2015: XOMA Will Present XOMA 358 Phase 1 Data at ENDO 2015 72 Appendix 74 Methodology 74 Coverage 74 Secondary Research 74 Primary Research 74 Expert Panel Validation 74 Contact Us 74 Disclaimer 75
List of Tables
Number of Products under Development for Hypoglycemia, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Clinical Stage Development, H1 2016 11 Comparative Analysis by Early Stage Development, H1 2016 12 Comparative Analysis by Unknown Stage Development, H1 2016 13 Products under Development by Companies, H1 2016 14 Hypoglycemia - Pipeline by Biodel Inc., H1 2016 15 Hypoglycemia - Pipeline by Eiger BioPharmaceuticals, Inc., H1 2016 16 Hypoglycemia - Pipeline by Eli Lilly and Company, H1 2016 17 Hypoglycemia - Pipeline by Heptares Therapeutics Limited, H1 2016 18 Hypoglycemia - Pipeline by Novartis AG, H1 2016 19 Hypoglycemia - Pipeline by Sanofi, H1 2016 20 Hypoglycemia - Pipeline by SkyePharma Plc, H1 2016 21 Hypoglycemia - Pipeline by Therakind Limited, H1 2016 22 Hypoglycemia - Pipeline by USV Limited, H1 2016 23 Hypoglycemia - Pipeline by XERIS Pharmaceuticals, Inc., H1 2016 24 Hypoglycemia - Pipeline by XOMA Corporation, H1 2016 25 Hypoglycemia - Pipeline by Zealand Pharma A/S, H1 2016 26 Assessment by Monotherapy Products, H1 2016 27 Number of Products by Stage and Target, H1 2016 29 Number of Products by Stage and Mechanism of Action, H1 2016 31 Number of Products by Stage and Route of Administration, H1 2016 33 Number of Products by Stage and Molecule Type, H1 2016 35 Hypoglycemia Therapeutics - Recent Pipeline Updates, H1 2016 56 Hypoglycemia - Dormant Projects, H1 2016 64 Hypoglycemia - Discontinued Products, H1 2016 65
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.